Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Apoptosis
HSP90 protects apoptotic cleavage of vimentin in geldanamycin-induced apoptosis
February 8th, 2006
According to recently published research from South Korea, heat shock protein 90 (HSP90) protects apoptotic cleavage of vimentin in geldanamycin-induced apoptosis. "HSP90 is of interest as an anticancer drug target because of its importance in maintaining the conformation, stability and function of the client proteins involved in signal transduction pathways leading to proliferation, cell cycle progression, and apoptosis. Geldanamycin, a specific antagonist of HSP90, binds directly to HSP90 and promotes proteolytic degradation of client proteins of HSP90." M.H. Zhang and colleagues, Seoul National University, wrote, "The aim of the present study was...
Source: Immunotherapy Weekly (2006-02-08)
|
